Prostate cancer (PCa) with neuroendocrine differentiation (NED) is tightly associated with hormone refractory PCa (HRPC), an aggressive form of cancer that is nearly impossible to treat. Determining the mechani...
Recently, a new morphologic classification of prostate cancer with neuroendocrine differentiation is proposed that includes usual prostate adenocarcinoma with NE differentiation, adenocarcinoma with Paneth cell NE differentiation, carcinoid tumor, small cell carcinoma, large-cell NE carcinoma (LCNEC), and ...
Lineage plasticity is a hallmark of cancer progression that impacts therapy outcomes, yet the mechanisms mediating this process remain unclear. Here, we introduce a versatile in vivo platform to interrogate neuroendocrine lineage transformation throughout prostate cancer progression. Transplanted mouse prostate...
Genome-wide DNA methylation analysis of metastatic biopsies from patients with castration-resistant prostate cancer reveals marked epigenetic differences between samples with adenocarcinoma and neuroendocrine histologies. An increasingly recognized resis
the tumors progress to CRPC by increasing cell cycle genes and eventually dedifferentiate toAR-negative disease with or without neuroendocrine features (neuroendocrine prostate cancer (NEPC)) (Fig.1e). Notably, the transcriptional changes correlated well with the protein level changes in an independent...
Neuroendocrine prostate cancer (NEPC) encompasses various clinical contexts, ranging from the de novo presentation of small cell prostatic carcinoma to a treatment-emergent transformed phenotype that arises from typical adenocarcinoma of the prostate. The development of resistance to potent androgen receptor...
Neuroendocrine (NE) cells are found in prostate tumors, and their incidence is considered a promising prognostic indicator for the development of androgen-independent disease. NE cells are derived from non-NE prostate cancer cells and secrete factors that can act in a paracrine manner to stimulate ...
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer that may either arise de novo or much more commonly after hormonal therapy for prostate adenocarcinoma. It is estimated that up to 30 % of late stage prostate cancers harbor a predominance of neuroendocrine diffe...
Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives Neuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma disease or as a result of transdifferentiation later in time, was descri... PJ Vlachostergios,CN Papandreou - 《Frontiers in Oncology》 被引量:...
Prostate cancer is a complex disease that affects millions of men globally, predominantly in high human development index regions. Patients with localized disease at a low to intermediate risk of recurrence generally have a favourable outcome of 99% over